---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-063737"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:30:39.567532+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Viridian Q4 2022 net loss $45.8M, cash $424.6M; THRIVE Ph3 enrolled

## Summary
- Net loss $45.8M in Q4 2022 vs $28.9M in Q4 2021; R&D expense $39.3M vs $22.4M.
- Cash, equivalents & short-term investments $424.6M as of Dec 31, 2022; runway into H2 2025.
- First patient enrolled in THRIVE Phase 3 trial of VRDN-001 for active TED; topline mid-2024.
- Initial proof-of-concept data for VRDN-001 in chronic TED expected Q2 2023.
- Appointed Scott Myers as President and CEO in February 2023.

## SEC filing metadata
- accession: 0001193125-23-063737
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312523063737/0001193125-23-063737-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312523063737/d478193d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-063737
- JSON: https://secwatch.observer/filing/0001193125-23-063737.json
- Plain text: https://secwatch.observer/filing/0001193125-23-063737.txt

## Key facts
- Earnings Releases
  Viridian Therapeutics, Inc.\DE reported financial results for the fourth quarter and full year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: On March 8, 2023, Viridian Therapeutics, Inc. (the “Company”), issued a press release reporting financial results for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312523063737/0001193125-23-063737-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.